Buy Or Sell FactSet Stock Ahead Of Upcoming Earnings?
CANADA - 2025/06/03: In this photo illustration, the FactSet Research Systems logo is seen displayed ... More on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
FactSet Research Systems (NYSE:FDS), a financial data and technology firm that offers software and information for investment management, is scheduled to release its Q3 earnings around June 23 (August fiscal year end). According to consensus estimates, earnings are projected to be $4.30 per share, a slight decline from $4.37 during the same period last year, while revenues are anticipated to rise by 5.1% year-over-year to $580.7 million. This growth is expected to be fueled by heightened demand from wealth and institutional buy-side clients, with organic subscription value – which refers to the recurring revenue the company anticipates generating annually from its existing subscription agreements – also likely to increase.
The company possesses a current market capitalization of $16 billion. Revenue for the past twelve months stood at $2.3 billion, and it was profitable in operational terms, reporting $711 million in operating profits and a net income of $543 million. Nevertheless, for those seeking potential upside with less volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and yielding returns exceeding 91% since its inception.
View earnings reaction history of all stocks
Some insights regarding one-day (1D) post-earnings returns:
Further data concerning observed 5-Day (5D) and 21-Day (21D) post-earnings returns is compiled along with the statistics in the table below.
FDS 1D, 5D, and 21D Post Earnings Return
A relatively less risky approach (although not beneficial if the correlation is low) is to assess the correlation between short-term and medium-term post-earnings returns, identify the pair with the strongest correlation, and execute the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can choose to go 'long' for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) time frame. Note that the correlation 1D_5D refers to the relationship between 1D post-earnings returns and the subsequent 5D returns.
FDS Correlation Between 1D, 5D, and 21D Historical Returns
Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000), generating strong returns for investors. Additionally, if you're looking for potential upside with a smoother experience compared to an individual stock like FactSet Research Systems, consider the High Quality portfolio, which has surpassed the S&P, achieving over 91% returns since inception.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
25 minutes ago
- Wall Street Journal
Bank of Canada to Monitor Signs of Broader Job-Market Weakness
OTTAWA—Bank of Canada officials are tracking labor-market conditions to determine whether job cuts in trade-exposed sectors like manufacturing start spreading in other parts of the economy, Gov. Tiff Macklem said Wednesday. In the event that unfolds, it would signal trade uncertainty and higher tariffs are dampening demand, and may exert downward pressure on inflation, said Macklem, according to prepared remarks set for delivery at a board of trade luncheon in St. John's, Newfoundland.
CNBC
31 minutes ago
- CNBC
Stocks making the biggest moves midday: Nucor, Sunrun, Affirm, Zoetis, Circle and more
Check out the companies making headlines in midday trading. Steel stocks– Shares of steel producer Nucor jumped more than 3%. The company issued rosy guidance for its second-quarter earnings, calling for $2.55 to $2.65 per share, while FactSet consensus estimates sought $2.36 per share. In contrast, Steel Dynamics' guidance fell short of Wall Street's estimates, ranging from $2.00 to $2.04 per share, while analysts were looking for $2.73 per share. The stock slipped 1%. The moves follow the completion of the Nippon Steel-U.S. Steel deal . Shares of peer companies Cleveland-Cliffs and Reliance were little changed. Scholar Rock Holding — Shares jumped nearly 15% after the biotech reported its experimental drug showed it was able to help patients taking Eli Lilly 's obesity drug lose less muscle as they shed pounds. Lilly shares were down slightly. Affirm — The consumer finance stock rose 3% after Affirm announced the creation a new loan sale facility with Prudential's PGIM Fixed Income business. Prudential will buy as much as $500 million of Affirm's consumer loans at any one time, with a total investment of $3 billion over the next three years. Sunrun — Shares of the solar company rose 5% despite a downgrade to sector perform from outperform by RBC Capital Markets. The stock on Tuesday recorded its biggest one-day loss in its history amid a sell-off in solar names. Other solar stocks including Enphase Energy , which was up nearly 5%, and Solaredge , which gained 7%, were also higher. Bausch Health — Shares climbed 8% after John Paulson, its nonexecutive chair, acquired 3.6 million shares of the pharma company's stock. The purchase came on the heels of a $14.7 million purchase disclosed last week. Paulson now owns about 9% of the company's outstanding stock. CERo Therapeutics Holdings — Stock in the immunotherapy company pulled back more than 30%. On Tuesday, the U.S. Food and Drug Administration gave the company's acute myeloid leukemia drug CER-1236 an orphan drug designation . Shares rose more than 188% on that news. Chemours — The chemical stock rose 8% after an updated second-quarter forecast showed weakness in a key profit metric. Chemours said it expects consolidated adjusted EBITDA — or earnings before interest, taxes, depreciation and amortization — of $215 million to $225 million for the period. Wall Street expectations called for $236 million, according to FactSet. Regencell Bioscience — Shares dropped 26% after an eyewatering move higher this week . The Hong Kong-based developer of traditional Chinese herbal treatments has said it can treat childhood ADHD and autism. Regencell jumped 30% on Tuesday, and soared 283% Monday, following a 38-for-1 stock split. It's gained more than 59,000% this year. Oracle — The software company gained more than 1% after Guggenheim raised its price target on the stock to the highest on the Street. Analyst John DiFucci said Oracle is "on the precipice of a narrative shift that has been decades of technology innovation in the making." Zoetis — Shares of the animal health company slipped 3% following a downgrade at Stifel to hold from buy. The firm said it expects Zoetis' revenue growth to decelerate further amid increasing competition. Korn Ferry — Shares of the consulting firm gained 9% after fourth-quarter results surpassed analyst estimates on the top and bottom line. Korn Ferry earned $1.32 per share, excluding items, on revenue of $712 million. Analysts polled by FactSet expected a profit of $1.26 per share and revenue of $689.9 million. Circle Internet Group — Stock in the company behind stablecoin USDC advanced almost 16%, after the U.S. Senate passed the GENIUS bill . The legislation is the first of its kind and establishes federal guidelines for digital dollars that are pegged to the greenback. — CNBC's Brian Evans, Sarah Min, Michelle Fox, Alex Harring, Fred Imbert, Yun Li, Jesse Pound and Darla Mercado contributed reporting.
Bloomberg
31 minutes ago
- Bloomberg
Mortgage Rates in US Fall for a Third Week, Slipping to 6.81%
Mortgage rates in the US dropped for a third week, sliding to the lowest level since the middle of May. The average for 30-year, fixed loans was 6.81%, down from 6.84% last week, Freddie Mac said in a statement.
